FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306174526> ?p ?o ?g. }

• W4306174526 endingPage "1135" @default.
• W4306174526 startingPage "1122" @default.
• W4306174526 abstract "The therapeutic efficacy of histone deacetylase inhibitors (HDACi) for hematologic malignancies and solid tumors is attributed to their ability to remodel chromatin, normalize dysregulated gene expression, and inhibit repair of damaged DNA. Studies on the interactions of HDACi with PARP inhibitors in hematologic cancers are limited, especially when combined with chemotherapeutic agents. Exposure of hematologic cancer cell lines and patient-derived cell samples to various HDACi resulted in a significant caspase-independent inhibition of protein PARylation, mainly catalyzed by PARP1. HDACi affected the expression of PARP1 at the transcription and/or post-translation levels in a cell line-dependent manner. HDACi-mediated inhibition of PARylation correlated with decreased levels and phosphorylation of major proteins involved in DNA repair. Combination of HDAC and PARP1 inhibitors provided synergistic cytotoxicity, which was further enhanced when combined with a chemotherapeutic regimen containing gemcitabine, busulfan and melphalan as observed in lymphoma cell lines. Our results indicate that the anti-tumor efficacy of HDACi is partly due to down-regulation of PARylation, which negatively affects the status of DNA repair proteins. This repair inhibition, combined with the high levels of oxidative and DNA replication stress characteristic of cancer cells, could have conferred these hematologic cancer cells not only with a high sensitivity to HDACi but also with a heightened dependence on PARP and therefore with extreme sensitivity to combined HDACi/PARPi treatment and, by extension, to their combination with conventional DNA-damaging chemotherapeutic agents. The observed synergism of these drugs could have a major significance in improving treatment of these cancers." @default.
• W4306174526 created "2022-10-14" @default.
• W4306174526 creator A5004417292 @default.
• W4306174526 creator A5029237145 @default.
• W4306174526 creator A5051563559 @default.
• W4306174526 creator A5081752664 @default.
• W4306174526 creator A5089724364 @default.
• W4306174526 date "2022-10-14" @default.
• W4306174526 modified "2023-10-16" @default.
• W4306174526 title "HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: Implications for their use in combination with PARP inhibitors and chemotherapeutic drugs" @default.
• W4306174526 cites W154704142 @default.
• W4306174526 cites W1965006127 @default.
• W4306174526 cites W1972149587 @default.
• W4306174526 cites W1980842169 @default.
• W4306174526 cites W1983759525 @default.
• W4306174526 cites W1992456066 @default.
• W4306174526 cites W2006945874 @default.
• W4306174526 cites W2013715448 @default.
• W4306174526 cites W2019778397 @default.
• W4306174526 cites W2022811243 @default.
• W4306174526 cites W2026355284 @default.
• W4306174526 cites W2035915355 @default.
• W4306174526 cites W2036723718 @default.
• W4306174526 cites W2040506727 @default.
• W4306174526 cites W2040855010 @default.
• W4306174526 cites W2048108896 @default.
• W4306174526 cites W2060247906 @default.
• W4306174526 cites W2061019285 @default.
• W4306174526 cites W2103461425 @default.
• W4306174526 cites W2116735990 @default.
• W4306174526 cites W2162951729 @default.
• W4306174526 cites W2179097847 @default.
• W4306174526 cites W2234974003 @default.
• W4306174526 cites W2271364972 @default.
• W4306174526 cites W2313302556 @default.
• W4306174526 cites W2314558022 @default.
• W4306174526 cites W2401586223 @default.
• W4306174526 cites W2514390888 @default.
• W4306174526 cites W2791798082 @default.
• W4306174526 cites W2884338874 @default.
• W4306174526 cites W2984496473 @default.
• W4306174526 cites W3081569548 @default.
• W4306174526 cites W3091302717 @default.
• W4306174526 cites W3152687170 @default.
• W4306174526 cites W3164714401 @default.
• W4306174526 cites W3191826011 @default.
• W4306174526 cites W3204420821 @default.
• W4306174526 cites W3212265315 @default.
• W4306174526 cites W3217609143 @default.
• W4306174526 cites W4200445528 @default.
• W4306174526 cites W4213133218 @default.
• W4306174526 cites W4226412666 @default.
• W4306174526 doi "https://doi.org/10.18632/oncotarget.28278" @default.
• W4306174526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36243940" @default.
• W4306174526 hasPublicationYear "2022" @default.
• W4306174526 type Work @default.
• W4306174526 citedByCount "2" @default.
• W4306174526 countsByYear W43061745262022 @default.
• W4306174526 countsByYear W43061745262023 @default.
• W4306174526 crossrefType "journal-article" @default.
• W4306174526 hasAuthorship W4306174526A5004417292 @default.
• W4306174526 hasAuthorship W4306174526A5029237145 @default.
• W4306174526 hasAuthorship W4306174526A5051563559 @default.
• W4306174526 hasAuthorship W4306174526A5081752664 @default.
• W4306174526 hasAuthorship W4306174526A5089724364 @default.
• W4306174526 hasBestOaLocation W43061745261 @default.
• W4306174526 hasConcept C121608353 @default.
• W4306174526 hasConcept C134935766 @default.
• W4306174526 hasConcept C143425029 @default.
• W4306174526 hasConcept C182979987 @default.
• W4306174526 hasConcept C2778305200 @default.
• W4306174526 hasConcept C2778480876 @default.
• W4306174526 hasConcept C2778502085 @default.
• W4306174526 hasConcept C502942594 @default.
• W4306174526 hasConcept C54355233 @default.
• W4306174526 hasConcept C552990157 @default.
• W4306174526 hasConcept C55493867 @default.
• W4306174526 hasConcept C64927066 @default.
• W4306174526 hasConcept C82381507 @default.
• W4306174526 hasConcept C86803240 @default.
• W4306174526 hasConcept C96232424 @default.
• W4306174526 hasConcept C98274493 @default.
• W4306174526 hasConceptScore W4306174526C121608353 @default.
• W4306174526 hasConceptScore W4306174526C134935766 @default.
• W4306174526 hasConceptScore W4306174526C143425029 @default.
• W4306174526 hasConceptScore W4306174526C182979987 @default.
• W4306174526 hasConceptScore W4306174526C2778305200 @default.
• W4306174526 hasConceptScore W4306174526C2778480876 @default.
• W4306174526 hasConceptScore W4306174526C2778502085 @default.
• W4306174526 hasConceptScore W4306174526C502942594 @default.
• W4306174526 hasConceptScore W4306174526C54355233 @default.
• W4306174526 hasConceptScore W4306174526C552990157 @default.
• W4306174526 hasConceptScore W4306174526C55493867 @default.
• W4306174526 hasConceptScore W4306174526C64927066 @default.
• W4306174526 hasConceptScore W4306174526C82381507 @default.
• W4306174526 hasConceptScore W4306174526C86803240 @default.
• W4306174526 hasConceptScore W4306174526C96232424 @default.
• W4306174526 hasConceptScore W4306174526C98274493 @default.

• next